Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982 May;13(5):665-73.
doi: 10.1111/j.1365-2125.1982.tb01434.x.

Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis

Clinical Trial

Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis

R E Bullingham et al. Br J Clin Pharmacol. 1982 May.

Abstract

1 A 10 h study of plasma drug concentrations of the opiate buprenorphine after use was designed because a previous 3 h study had shown that peak plasma drug concentrations in some patients had not occurred by 3 h after the sublingual dose. 2 Fifteen postoperative patients were studied: at 3 h after a 0.3 mg intravenous dose five patients received a sublingual preparation of 0.4 mg of buprenorphine, five 0.8 mg of buprenorphine and five placebo. Plasma drug concentrations of buprenorphine were measured by specific radioimmuno-assay. 3 Plasma drug concentrations after sublingual buprenorphine were significantly higher than those in the placebo group by 1 h. They remained significantly higher over the succeeding nine hours. The mean time to peak plasma drug concentration was about 200 min in both the 0.4 mg and 0.8 mg groups (range 90-360 min). The plasma drug concentrations in the 0.8 mg group were approximately twice those in the 0.4 mg group; the ratio of the relative systemic availabilities was similarly 1.8:1. The absolute systemic availability was estimated at about 55% for both groups. Uptake of buprenorphine from the sublingual site was essentially complete by 5 h after the dose was given. 4 The implications for the timing of sublingual doses in clinical use are discussed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Practitioner. 1966 Jan;196(171):125-6 - PubMed
    1. J Theor Biol. 1968 Aug;20(2):173-201 - PubMed
    1. J Pharm Pharmacol. 1971 Dec;23:68S-72S - PubMed
    1. J Pharm Sci. 1972 Nov;61(11):1785-91 - PubMed
    1. J Pharmacokinet Biopharm. 1976 Oct;4(5):443-67 - PubMed

Publication types

LinkOut - more resources